Robert Cook-Deegan’s Viewers’ Guide To the Super Bowl of Gene Patent Cases 2

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Does Myriad have rights to BRCA2?

The race to find mutations associated with inherited risk of breast cancer started with Mary-Claire King’s announcement of linkage to chromosome 17 in fall 1990. As Kevin Davies documented in his book Breakthrough, it is widely accepted that the team led by Mark Skolnick of the University of Utah and Myriad Genetics won that race to find BRCA1. They cloned and sequenced the gene and identified the first high-risk variants several months ahead of King and other rival groups in the UK, France and the United States. Utah/Myriad filed the first patent applications on BRCA1.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Pfizer External Research & Grants’ “Improving Breast Cancer Quality of Care via Meaningful Capacity Building in Sub-Saharan Africa,” powered by EveryGrant, has announced grants totaling more than $900,000 for addressing inequities and improving the quality of breast cancer care in Sub-Saharan Africa.
It started innocuously enough. I looked in the mirror and noticed a pigmented area on my scalp just into the hairline. Like many patients, thoughts started running through my head: “Maybe it’s nothing.” Looking at my Outlook calendar, it was packed morning-to-night with meetings, patients, and travel, so I decided I would get that spot checked out the minute I had “time.” 

In the morning of May 28, presumably before turning off the lights and closing the office door, someone at the now defunct NCI Office of Communications and Public Liaision decided to post a farewell message to the cancer community.  The message, posted on multiple social media accounts, read: We’re taking a pause here - but...

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login